Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (486)	10/8/2003 7:37:29 PM
From: SemiBull	Read Replies (1) \| Respond to of 668

Curis Issued U.S. Patent on Hedgehog Proteins Wednesday October 8, 8:48 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 8, 2003--Curis, Inc. (NASDAQ: CRIS - News) today announced that it has been issued U.S. patent 6,630,148, entitled "Compositions Comprising Hedgehog Proteins." The claims of this patent cover pharmaceutical compositions containing Hedgehog signaling proteins. The Hedgehog signaling proteins in the compositions are characterized in terms of the DNA sequences that encode the proteins, as well as certain biological activities associated with the pathway. The Hedgehog family of signaling proteins controls one of the major regulatory pathways responsible for the development and maintenance of tissues of the body and has been shown to be involved in repair and regeneration when those tissues are damaged or traumatized. Curis is using the Hedgehog signaling pathway as a technology platform to develop drug candidates to treat neurological disorders, cancer, cardiovascular disease, and hair growth disorders. Daniel Passeri, Curis' President and Chief Executive Officer, said, "This new patent represents another significant piece of the core intellectual property protection that Curis has constructed around the Hedgehog signaling pathway. This emphasis on building a solid foundation of patent protection is one of the major factors that has enabled Curis to establish several prominent pharmaceutical collaborations during the last twelve months. We expect that our patent position will continue to provide us with additional collaborative opportunities for Hedgehog technologies in the future." About Curis, Inc. Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the Curis web site at www.curis.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release. Contact: For Curis, Inc. Christopher U. Missling, Ph.D., 617-503-6587 or Marc F. Charette, Ph.D., 617-503-6629 Source: Curis, Inc.